ReviewWorld journal of gastrointestinal surgery2025
Acellular mucin in neoplastic and non-neoplastic conditions of the lower gastrointestinal tract.
Review in World journal of gastrointestinal surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acellular mucin refers to pools of mucin without epithelial component, oftentimes harboring inflammatory cells. Acellular mucin can be observed in both neoplastic and non-neoplastic lower gastrointestinal (GI) conditions. While mucinous neoplasms are classified and staged using established guidelines, interobserver variability occurs when acellular mucin pools are encountered, leading to inconsistent interpretation and staging. In particular, acellular mucin found in regional lymph nodes of colorectal adenocarcinoma patients who have not received treatment presents a diagnostic challenge, as its prognostic implication is not clearly defined. Acellular mucin is also commonly seen in treated colorectal adenocarcinoma, post neoadjuvant therapy. Although acellular mucin is not counted toward T or N staging in this setting, variation in how pathologists report and stage these cases persists. Acellular mucin can also be seen in non-neoplastic specimens, such as those from interval appendectomies, appendiceal diverticula, colonic diverticulitis, volvulus, and Crohn's disease where it may mimic a neoplastic lesion. Acellular mucin in this setting is often a byproduct of inflammation, increased luminal pressure, and mural defect. This review highlights the clinical relevance and diagnostic complexity of acellular mucin in pathologic conditions of the lower GI tract. Further studies are needed to clarify its prognostic value and develop standardized guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.